Document is current
Any future updates will be listed below
-
Authors
Senent, Yaiza
Fresquet, Vicente
Jiménez, Victoria
Valencia, Karmele
Exposito, Francisco
Martín-Úriz, Patxi San
Camps, Gracián
Fernández-Pierola, Eva
de Córdoba, Borja Ruiz-Fernández
González-Huarriz, Marisol
Tamayo, Ibon
Remírez, Ana
Moreno, Haritz
Serrano, Diego
Ajona, Daniel
Alonso, Marta M.
Lecanda, Fernando
Pineda-Lucena, Antonio
Prósper, Felipe
Sanmamed, Miguel F.
Calvo, Alfonso
Martinez-Climent, Jose A.
Pio, Ruben
-
Funding
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (FPU18/02638, RYC RYC2022-038084-I, PID2020-115875RBB-I00)
Instituto de Salud Carlos III (PI23/00573, PI22/00983, PI23/00573)
Centro de Investigación Biomédica en Red de Cáncer (CB16/12/00489, CB16/12/00443, CB16/12/00489, CB16/12/00443)
Arnal Planelles Foundation
German Jose Carreras Leukemia research Foundation
- License Information
-
More Information
Article History
Received: 17 January 2025
Accepted: 13 May 2025
First Online: 30 May 2025
Declarations
:
: JAM-C received funding for research from Roche-Genentech, Bristol Myers Squibb-Celgene, Janssen, Regeneron, Priothera Pharmaceuticals, Palleon Pharmaceuticals, AstraZeneca, and K36 Therapeutics; is inventor on a patent ‘Genetically engineered animal models for multiple myeloma’ licensed to MIMO Biosciences; and is founder, holder of stock options, and royalties in MIMO Biosciences, all unrelated to this study. The other authors declare no conflict of interest.The other authors declare no conflict of interest.
